Scientific Team


MedSIR strives to preserve the value of scientific knowledge, adding organizational structures that improve human and economic resource efficiency




    Scientific Support

    With a Master’s Degree in Biomedical Sciences and a Postgraduate Specialization School in Clinical Biochemistry from the University of Bari (Italy), Andrea confirmed his desire to deepen his knowledge in the field of Molecular Oncology and Translational Medicine. In 2007, Andrea started his work experience as Research Fellow at the National Cancer Institute of Bari (Italy), where his research activity was mainly focused on the identification of new potential molecular biomarkers of prognosis and response to treatment in breast cancer and colorectal tumors.

    In 2013, Andrea decided to give an international scope to his research training, moving to Barcelona (Spain) with a European Marie Skłodowska-Curie fellowship under his arm. After an experience as Visiting Research Fellow at the Medical University of Vienna (Austria), Andrea obtained his PhD in Biomedicine from the University of Barcelona in 2016 with a translational-minded thesis about the role of TGF-β on “stemness” properties in human hepatocellular carcinoma.

    As part of his second Master’s Degree in Management and Monitoring of Clinical Trials from the CEU Cardenal Herrera University of Valencia (Spain), Andrea joined MedSIR in April 2017 as Project Management Assistant. His passion for Health & Life Sciences, his strong experience in basic/translational research in Oncology with a proven publication track record and his motivation for professional challenges have played a key role in Andrea’s advancement to Site Manager and Medical Writer since October 2017.

    Andrea speaks English, Spanish, and Italian fluently.



    Network Specialist

    After obtaining a Chemistry and a Biochemistry Degree from the University of Salamanca and a Molecular Biotechnology Master’s Degree from the University of Barcelona, Roldán decided he wanted to study tumor metabolism in order to find new diagnostic methods and therapeutic approaches to fight cancer. In 2014 he obtained a PhD in Molecular Biology with a focus in cancer metabolomics in the University of Barcelona, and subsequently he worked as a Post-Doc Researcher, Project Manager and Assistant Professor in the University of Barcelona.

    During his years of experience in scientific research, Roldán acquired expertise not only in the molecular study of cancer and in many different biochemical analysis techniques, but also in setting up new methods and workflows, supervising junior scientists and coordinating both public and privately founded academic-industry collaborative projects.

    In 2016 he started a Master’s Degree in Medical Studies Monitoring by the Barcelona Official College of Physicians, and in 2017 he joined MedSIR fascinated by the company’s approach to strategically-designed, patient-centered, investigator-driven clinical trials in oncology. His expertise in health sciences, his passion about translational medical research and his experience with multidisciplinary projects make him an ideal addition to MedSIR’s team, and a fierce enthusiast of our vision of developing innovative ways to improve the lives of cancer patients worldwide.

    Roldán speaks English, Spanish, and Catalan fluently.



    Network Support

    Eloy obtained his bachelor’s degree in Biomedicine at the University of Barcelona. Shortly after, he carried out a master’s program in Biomedicine and Cancer Research at the Faculty of Medicine of the Hospital Clínic of Barcelona.

    At the end of his bachelor, he performed a one-year internship at the Netherlands Cancer Institute (NKI) in Amsterdam. His research activity was mainly focused on the study of the sensitivity of several molecular inhibitors in combination with the standard of care treatment in Glioblastoma. As part of his master’s internship, Eloy collaborated with a prestigious research group at the Josep Carreras Leukaemia foundation in Barcelona, dedicated to find new therapies for Leukaemia. He studied the depletion of cancer stem cells in leukaemia using Bromocriptine, a dopamine agonist used to treat pituitary tumors and other diseases such as Parkinson.

    In 2014, he received his master’s degree and shortly thereafter, he relocated to the Netherlands to commence a PhD track under the supervision of prof. Marc Vooijs at the department of radiation oncology, Maastricht University. His research involved basic and therapeutic aspects of the HIF and NOTCH signaling pathways for cancer treatment. One of the most exciting achievements of his PhD was the generation of several knock-out cell lines using the CRISPR/CAS9 technology for a set of different oncogenes.

    Eloy speaks English, Spanish, Italian and Catalan fluently and has working knowledge of Dutch. His main passion is travelling but he also enjoys a large set of activities such as CrossFit training, trekking, chess and hanging out with friends.



    Medical Scientist

    Isabel Tena, MD, is a graduate of University of Valencia Medical School. She trained in internal medicine and oncology at Valencian Institute of Oncology in Spain and became board certified in Medical Oncology in 2006.

    She took her position as a staff member at Provincial Hospital of Castellon in 2006 and continued her practice there for 11 years. She gradually moved to the field of lung cancer and neuroendocrine tumors. Both during her fellowship and her clinical practice she was involved in phase 2 and 3 trials execution for 15 years, always with the position of Co-Investigator.

    In 2016 she was granted by the Spanish Society of Medical Oncology (SEOM) Foundation in 2016 and enrolled the National Institutes of Health (NIH) as a Research Collaborator in January 2017 (NIH/NICHD). In 2018 following the discovery that hypoxia-driven tumors present a deficitary homologous recombination DNA-repair pathway, Isabel developed a clinical trial with a PARP inhibitor in combination with temozolomide (“Phase II study of talazoparib combined with temozolomide (Temodar®) in metastatic pheochromocytoma/paraganglioma (mPPGL)”).

    At NIH, Isabel discovered the beauty of translational research and the passion of making ideas translate into clinical development. In January 2019 she moved to MedSIR with the goal of impacting lives of cancer patients.




    Medical Scientist


    Medical Scientist

    Statistical Expert

MedSIR is always looking to add talented individuals to its team in a number of roles. If you are interested in getting us to know you better, please visit our Work With Us page to submit your CV to us.

Careers 01
Careers 02
Careers 03